Ecolab Inc. (ECL) Stock Price & Analysis
Ecolab Inc. (ECL) rose 2.73% to USD 264.44 as of June 9, 2026 at 22:34 UTC, according to Nexqual real-time market data.
ECL last closed at USD 257.41; the session ranged USD 260.59–264.47 on volume of 1,537,014 shares. Market capitalization is $74.42B, with a 52-week range of USD 243.15–309.27 (NYQ). Source: Nexqual, June 9, 2026 at 22:34 UTC.
Key Statistics (as of June 9, 2026 at 22:34 UTC)
| Price | USD 264.44 |
|---|---|
| Change | ▲ 2.73% (up) |
| Previous Close | USD 257.41 |
| Open | USD 262 |
| Day Range | USD 260.59 – 264.47 |
| 52-Week Range | USD 243.15 – 309.27 |
| Volume | 1,537,014 shares |
| Market Cap | $74.42B |
| Exchange | NYQ |
Technical Analysis (ECL)
Nexqual's technical model rates ECL "NEUTRAL" based on 4 bullish and 3 bearish signals across 124 daily candles, as of June 9, 2026 at 22:34 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 57.15 (neutral) |
| vs SMA50 | Above (USD 261.09) |
| MACD | -0.27 (negative) |
Analyst Ratings (ECL)
Wall Street analysts rate ECL "Buy" based on 21 analysts, with a mean price target of USD 316.43 (range USD 260–345), per Nexqual as of June 9, 2026 at 22:34 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 21 |
| Mean Target | USD 316.43 |
| High Target | USD 345 |
| Low Target | USD 260 |
| Buy / Hold / Sell | 20 / 7 / 0 |
Earnings (ECL)
| Next Earnings Date | 2026-07-28 |
|---|---|
| EPS Estimate | USD 2.07 |
| Revenue Estimate | $4.40B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.7 vs est 1.7 ▲ beat |
| 2025-12-31 | USD 2.08 vs est 2.07 ▲ beat |
| 2025-09-30 | USD 2.07 vs est 2.07 ▼ miss |
| 2025-06-30 | USD 1.89 vs est 1.9 ▼ miss |
Source: Nexqual, June 9, 2026 at 22:34 UTC.
Financials & Fundamentals (ECL)
| Total Revenue | $16.45B |
|---|---|
| Revenue Growth (YoY) | +10.00% |
| Gross Margin | +44.37% |
| Operating Margin | +16.93% |
| Profit Margin | +12.80% |
| ROE | +22.43% |
| Debt / Equity | 92.37 |
| Current Ratio | 0.99 |
| Total Cash | $519.80M |
| Total Debt | $9.27B |
| Free Cash Flow | $1.59B |
Source: Nexqual, June 9, 2026 at 22:34 UTC.
Financial Health Score (ECL)
Nexqual rates Ecolab Inc.'s overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 22:34 UTC.
| Growth | Mixed — Revenue +2.2% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 44%, operating 17% |
| Balance Sheet | Weak — $520M cash vs $9.27B debt |
| Cash Flow | Solid — FCF $1.59B, 10% margin |
| Efficiency | Strong — ROE 22%, ROA 8.0% |
Ownership (ECL)
| Insider Ownership | +0.15% |
|---|---|
| Institutional Ownership | +94.02% |
| Shares Outstanding | 281.44M |
| Float | 280.84M |
| Short % of Float | +1.42% |
Source: Nexqual, June 9, 2026 at 22:34 UTC.
Leadership (ECL)
Ecolab Inc. is led by Christophe Beck (age 57), CEO, President & Chairman of the Board, per Nexqual as of June 9, 2026 at 22:34 UTC.
| CEO, President & Chairman of the Board | Christophe Beck (age 57) |
|---|---|
| Chief Financial Officer | Scott D. Kirkland (age 51) |
| Executive Vice President of Human Resources | Margeaux M. King (age 47) |
| Co-Chief Operating Officer of Global Markets | Darrell R. Brown (age 61) |
| Co-Chief Operating Officer of Global Businesses | Gregory Russell B. Cook (age 56) |
Major Backers & Investors (ECL)
Notable institutional backers of Ecolab Inc. include JPMorgan, Morgan Stanley, Gates Foundation Trust, according to Nexqual as of June 9, 2026 at 22:34 UTC.
Active Investors
| Investor | Stake |
|---|---|
| JPMorgan | 4.14% |
| Morgan Stanley | 2.77% |
| Gates Foundation Trust | 1.85% |
| Aristotle Capital Management, LLC | 1.32% |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.27% |
| Fidelity | 1.16% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 14.81% |
| BlackRock | 9.27% |
| State Street | 5.07% |
| Geode Capital | 2.13% |
Source: Nexqual, June 9, 2026 at 22:34 UTC.
From Ecolab Inc.'s Latest SEC 10-K Filing (filed 2026-02-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Today, we have $16 billion in annual sales, 48,000 associates and customers in more than 170 countries and 40 industries.
- As we expand the use of smart, connected devices, we believe our Pest Intelligence model will further contribute to our high-quality outcomes. ​ Global Life Sciences ​ This reportable segment consists of the Life Sciences operating segment. ​ Life Sciences ​ Life Sciences provides end-to-end cleaning and contamination control solutions to pharmaceutical and personal care manufacturers.
- We believe we are one of the leading suppliers of process purification solutions in Europe and North America and of contamination control solutions in Europe, with a growing presence in North America and other regions. ​ ​ 6 Table of Contents Additional Information ​ International Operations ​ We directly operate in approximately 100 countries outside of the United States through wholly-owned subsidiaries or, in some cases, through a joint venture with a local partner.
- This unique combination enables us to partner with customers to define what best-in-class looks like and scale it across their operations, helping them achieve peak performance.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| APD | Air Products and Chemicals, Inc | USD 282.98 | ▲ 0.22% |
| SHW | Sherwin-Williams Company (The) | USD 310.55 | ▲ 1.72% |
| CTAS | Cintas Corporation | USD 179.87 | ▲ 0.01% |
| DOV | Dover Corporation | USD 220.97 | ▲ 2.89% |
| PPG | PPG Industries, Inc. | USD 116.36 | ▲ 2.25% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:34 UTC. This page is informational and not investment advice.